Full-Time
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Senior
Cambridge, MA, USA
- PhD in Chemical engineering with a minimum of 0-2 year experience in industry or academia, a master’s degree with a minimum of 4 years of experience.
- Proven track record in process development.
- An ability to work as part of a team, engaging other scientists with complementary skill sets in the field of pharmaceutical development.
- A change agent mentality, proposing novel approach to challenging scientific questions and exploring new modeling approaches.
- Development of processes to consistently produce API with the required quality attributes using both batch and continuous platforms.
- Integrate closely with project team members such as Chemists and Analysts to develop API processes.
- Apply AI/Modeling to transform development from traditional data driven statistical approaches to more efficient and effective Digital Development.
- Use a strong background in Engineering to understand and apply strategies to control process quality, yield, cost safety and EcoDesign.
- Apply strong lab skills to deliver well designed experimental plans for process development across a wide range of unit operations.
- Perform required physiochemical analysis to understand process and characterize processes this includes but is not limited to HPLC, GC, DSC, PSD, KF, optical microscopy and a variety of PAT techniques.
- Assist in the development and deployment of digital twins for batch and continuous processes ensuring alignment with Quality by Design (QbD) principles.
- Work closely with process Industrialization and New Technology Engineering team to design and implement model predictive control strategies for drug substance manufacturing processes.
- Implement Risk Assessments during development to ensure key processes quality and safety risks are identified and mitigated throughout development.
- Lead Tech Transfer of processes to the Pilot Plant and Manufacturing, including support for technical and HSE safety reviews, review of Master Batch Records and campaign coverage for key batches.
- Author relevant section of regulatory filings, help prepare for Preapproval Inspections, respond to questions about regulatory filing and engage proactively with regulatory agencies through external engagement.
- Provide concise technical presentations to communicate work to project teams, cross functional teams and management. Document all work on projects and continuous improvements in eLNB experiments and summarize in Technical Reports.
- Establish/extend external network by providing leadership on academic, industrial, or government sponsored collaborations. Steer collaboration projects to address gaps in scientific knowledge.
- Familiar with PAT and common off-line analytical techniques such as HPLC, GC and NMR.
- Modeling experience using gPROMS, DynoChem, Matlab, Python or similar programming languages.
- Some knowledge in Multivariate Analysis, chemometrics and statistics.
- Experience in the development and scale-up of continuous processes.
Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Dupixent's potential approval could make it the first targeted treatment for bullous pemphigoid.
- Sarclisa's expanded approval offers new revenue streams in the oncology market.
- Sanofi's €5 billion share buyback program indicates strong financial health.
What critics are saying
- Increased competition in multiple myeloma treatments may impact Sarclisa's market share.
- €5 billion share buyback could limit capital for R&D investments.
- Regulatory challenges may delay approval of new drugs like Tolebrutinib.
What makes Sanofi unique
- Sanofi's Dupixent shows promise in treating bullous pemphigoid, a rare skin disease.
- Sarclisa's approval in Japan and EU strengthens Sanofi's oncology portfolio.
- Sanofi's partnership with BrightInsight enhances digital health solutions for specialty therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained
Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850...
Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M
Approval offers access to new treatment options for newly diagnosed MM patientsApproval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myelomaParis, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ phase 3 study.Olivier NatafGlobal Head, Oncology“In recent years, new multiple myeloma cases have increased steadily in Japan and other Asian-Pacific nations, creating a need for new treatment approaches, particularly in the front-line setting. While Sarclisa-based combinations have been approved for relapsed or refractory patients in Japan, this approval represents the first indication for certain newly diagnosed patients. We are pleased to offer physicians an important new option for their patients earlier in the treatment journey, building upon our continued commitment to advancing innovative oncology treatments in difficult-to-treat hematologic malignancies around the world.”In Japan, Sarclisa was launched in August 2020 and has been approved for four different treatment regimens (in combination with pomalidomide and dexamethasone, as monotherapy, in combination with carfilzomib and dexamethasone, or in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma). In addition, Sarclisa has front-line approvals in the EU and the US. In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are not eligible for autologous stem cell transplant, as well as Sarclisa in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with relapsed or refractory MM who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity
Sanofi’nin sağlık sektöründe katma değer yaratacak yenilikçi fikirlerin gelişimine destek olmak için Endeavor ile birlikte hayata geçirdiği Girişimcilik Programı PharmUp’ın 6. dönem başvuruları başladı.Türkiye’nin girişimcilik alanındaki köklü kurumlarından Endeavor iş birliğinde gerçekleşecek 6. dönem takvimine göre, başvurular 25 Şubat 2025 tarihine kadar sanofi.com.tr/tr/pharmup üzerinden yapılabilecek. Yeni dönemin kategorileri Akıllı Sağlık Cihazları ve Diagnostik Çözümler (giyilebilir teknolojiler ve hızlı test araçları), Medikal Eğitim ve İletişim Araçları, Sağlıklı Yaşam Çözümleri, Dijital Sağlık ve Teletıp, Veri Yönetimi ve Analitiği, Kurumsal Dijital Dönüşüm olarak belirlendi.Sağlık sektöründe hastaların hayatını iyileştirme adına dijital çözümler üreten fikirlerin hayat bulduğu program PharmUp’ta seçilecek girişimler, mentorluk desteği ve eğitimler içeren 3 aylık hızlandırma dönemine başlayacak. Bu süreçte ürünlerini olgunlaştıran start-up’lar, sonrasında gerçekleştirilecek Demo Day ile sektörün önde gelen isimlerine projelerini tanıtma şansı bulacak ve Sanofi ile iş birliği fırsatı sunulacak. Bunlara ek olarak, programa katılacak girişimciler arasından belirlenecek kişiler, Paris’te gerçekleşen Viva Technology Fuarı’na Sanofi sponsorluğunda katılma imkânı bulacak.PharmUp’ta 2019’dan beri 27 girişimciye destek verildiİlki 2019 yılında gerçekleşen programa, bugüne kadar toplamda 300’e yakın girişimci başvuru yaptı